Publication | Open Access

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

OncologyErlotinib Versus ErlotinibMedicineMetronomic TherapyBronchial NeoplasmStandard First-line ChemotherapyPharmacotherapyCancer TreatmentPharmacologyLung Cancer